

GI and HEPATOLOGY, ANCILLARY REFERRAL FORM (A-M)

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:		State: Zip:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code

- | | | |
|---|---|---|
| ☐ K50.90 Crohn's disease, unspecified | ☐ A04.7 enterocolitis due to <i>Clostridium difficile</i> | ☐ B96.81 <i>H. pylori</i> infection |
| ☐ K52.832 lymphocytic colitis | ☐ K51.91 ulcerative colitis, unspecified | ☐ K52.2 chronic diarrhea, noninfectious |
| ☐ K76.82 hepatic encephalopathy | ☐ K52.839 microscopic colitis | ☐ K74.3 primary biliary cholangitis |
| | ☐ K92.2 gastrointestinal hemorrhage, unspecified | ☐ Other: _____ |

Labs & Procedures (please send copies of the most recent applicable results)

- ☐ CMP ☐ *C diff* toxin ☐ *C diff* PCR ☐ antimitochondrial antibody ☐ colonoscopy with tissue biopsy, date: _____

Treatment History

Current medication(s) with date(s) started: _____
 Prior medication(s) with dates of use: _____

PRESCRIPTION

☐ DAW

Medication	Dose/Strength	Directions/Sig	Quantity	Refills
☐ balsalazide	750mg capsule			
☐ budesonide	☐ 3mg DR capsule (Entocort EC) ☐ 4mg DR capsule (Tarpeyo) ☐ 6mg ER capsule (Ortikos) ☐ 9mg ER tablet (Uceris)			
☐ cholestyramine	4g packet			
☐ colestipol	☐ 5g packet ☐ 1g tablet			
☐ Difidol	200mg tablet	take 1 tablet by mouth twice daily for 10 days		
☐ mesalamine	☐ 0.375g ER capsule (Apriso) ☐ 4g rectal kit (Rowasa) ☐ 4g/60mL enema (Rowasa) ☐ 250mg ER capsule (Pentasa) ☐ 400mg DR capsule (Delzicol) ☐ 500mg ER capsule (Pentasa) ☐ 800mg DR tablet (Asacol HD) ☐ 1000mg suppository (Canasa) ☐ 1.2g DR tablet (Lialda)			

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

GI and HEPATOLOGY, ANCILLARY REFERRAL FORM (M-Z)

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:	State:	Zip:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code

- | | | |
|---|---|---|
| ☐ K50.90 Crohn's disease, unspecified | ☐ A04.7 enterocolitis due to <i>Clostridium difficile</i> | ☐ B96.81 <i>H. pylori</i> infection |
| ☐ K52.832 lymphocytic colitis | ☐ K51.91 ulcerative colitis, unspecified | ☐ K52.2 chronic diarrhea, noninfectious |
| ☐ K76.82 hepatic encephalopathy | ☐ K52.839 microscopic colitis | ☐ K74.3 primary biliary cholangitis |
| | ☐ K92.2 gastrointestinal hemorrhage, unspecified | ☐ Other: _____ |

Labs & Procedures (please send copies of the most recent applicable results)

- ☐ CMP ☐ *C diff* toxin ☐ *C diff* PCR ☐ antimitochondrial antibody ☐ colonoscopy with tissue biopsy, date: _____

Treatment History

Current medication(s) with date(s) started: _____
 Prior medication(s) with dates of use: _____

PRESCRIPTION

☐ DAW

Medication	Dose/Strength	Directions/Sig	Quantity	Refills
☐ megestrol	Susp: ☐ 40mg/mL ☐ 400mg/10mL ☐ 625mg/5mL ☐ 800mg/20mL Tabs: ☐ 20mg ☐ 40mg			
☐ octreotide	IM kit: ☐ 20mg ☐ 30mg PFS: ☐ 50µg/mL ☐ 100µg/mL Vial: ☐ 50µg/mL ☐ 100µg/mL ☐ 200µg/mL			
☐ sulfasalazine	☐ 500mg tab ☐ 500mg DR tab			
☐ Talicia	10mg-250mg-12.5mg caps	4 caps PO 3 times daily with food for 14 days		
☐ ursodiol	Caps: ☐ 200mg ☐ 300mg ☐ 400mg Tabs: ☐ 250mg ☐ 500mg			
☐ vancomycin	Caps: ☐ 125mg ☐ 250mg Soln: ☐ 250mg/5mL	_____ mg PO 4 times daily for _____ days		
☐ Xifaxan	550mg tablet	take 1 tablet by mouth twice daily		
Other:				

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

*By signing this form, I authorize Synergen Rx LLC and its employees to act as authorized agents on behalf of my office to obtain prior authorization through my patient's insurance plan and to facilitate the enrollment of the patient into patient assistance programs with manufacturers and other foundations.

GI BIOLOGICS REFERRAL FORM (E - R)

Phone: 404-585-7517
Fax: 404-900-9209
NPI: 1811550528
synergengerx.com

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:		State:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code

- ☐ **K50.90** Crohn's Disease, unspecified
☐ **K51.90** ulcerative colitis, unspecified
☐ Other: _____

Clinical History

Labs & Procedures (send copies of the most recent results)

- ☐ TB ☐ HBsAg
☐ colonoscopy with tissue biopsy, date: _____

height: _____ in/cm
weight: _____ lb/kg

Disease Staging

- ☐ MAYO score: _____
☐ CDAI score: _____

Severity: ☐ mild
☐ moderate
☐ severe

Treatment History

Current medication(s) with date(s) started: _____
Prior medication(s) with dates of use: _____

PRESCRIPTION

☐ DAW (deliver to ☐ patient ☐ office)

Medication	Route	Dose/Strength	Directions/Sig	Quantity	Refills
☐ Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed					
☐ Entyvio	☐ IV ☐ sub-Q	☐ vial: 300mg ☐ pen: 108mg/0.68mL	Intravenous ☐ Induction: 300mg IV at weeks 0, 2, & 6 ☐ Maintenance: 300mg IV every 8 weeks Subcutaneous ☐ Induction: 300mg IV at weeks 0 and 2 ☐ Maintenance: 108mg sub-Q every 2 wks		
☐ infliximab	☐ IV ☐ sub-Q	☐ vial: 100mg ☐ vial: 100mg ☐ pen: 120mg/mL ☐ PFS: 120mg/mL	☐ Induction: infuse _____mg (5mg/kg) IV at weeks 0, 2, & 6 Maintenance ☐ IV: _____mg (5 or 10 mg/kg) every _____ weeks beginning week 14 ☐ inj: 120mg mg sub-Q every 2 weeks beginning week 10		0
☐ Rinvoq	PO	Tabs: ☐ 45mg Tabs: ☐ 15mg ☐ 30mg	Induction ☐ Crohn's: 45mg once daily x 12 weeks ☐ UC: 45mg once daily x 8 weeks Maintenance ☐ Crohn's: _____ mg PO once daily ☐ UC: _____ mg PO once daily	28	0

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

GI BIOLOGICS REFERRAL FORM (S - T)

Phone: 404-585-7517
Fax: 404-900-9209
NPI: 1811550528
synergengrx.com

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:		State:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code

- ☐ **K50.90** Crohn's Disease, unspecified
☐ **K51.90** ulcerative colitis, unspecified
☐ Other: _____

Clinical History

Labs & Procedures (send copies of the most recent results)

- ☐ TB ☐ HBsAg
☐ colonoscopy with tissue biopsy, date: _____

height: _____ in/cm
 weight: _____ lb/kg

Disease Staging

- ☐ MAYO score: _____
☐ CDAI score: _____

Severity: ☐ mild
☐ moderate
☐ severe

Treatment History

Current medication(s) with date(s) started: _____
 Prior medication(s) with dates of use: _____

PRESCRIPTION

☐ DAW (deliver to ☐ patient ☐ office)

Medication	Route	Dose/Strength	Directions/Sig	Quantity	Refills
☐	Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed				
☐ Simponi	sub-Q	☐ pen: 100mg/mL ☐ PFS: 100mg/mL	☐ Induction: inject 200mg at week 0 then inject 100mg at week 2 Maintenance ☐ inject 100mg sub-Q every 4 weeks ☐ other: _____ mg every _____ wks		0
☐ Skyrizi Crohn's	IV sub-Q	☐ vial: 600mg/10mL OBJ: ☐ 180mg/1.2mL ☐ 360mg/2.4mL	☐ Induction: 600mg IV at weeks 0, 4, & 8 ☐ Maintenance: _____ mg sub-Q every 8 weeks	30	0
☐ Skyrizi UC	IV sub-Q	vial: 600mg/10mL OBJ: ☐ 180mg/1.2mL ☐ 360mg/2.4mL	☐ Induction: 1,200mg IV at weeks 0, 4, & 8 ☐ Maintenance: _____ mg sub-Q every 8 weeks	60	0
☐ Tremfya	IV sub-Q	☐ vial: 200mg/20mL pen: ☐ 100mg/mL ☐ 200mg/2mL PFS: ☐ 100mg/mL ☐ 200mg/2mL	☐ Induction: 200mg IV at weeks 0, 4, and 8 ☐ Maintenance: ☐ 100mg sub-Q every 8 weeks ☐ 200mg sub-Q every 4 weeks	60	0

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

GI BIOLOGICS REFERRAL FORM (U - Z)

Phone: 404-585-7517
Fax: 404-900-9209
NPI: 1811550528
synergenrx.com

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:	State:	Zip:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code ☐ K50.90 Crohn's Disease, unspecified ☐ K51.90 ulcerative colitis, unspecified ☐ Other: _____	Clinical History Labs & Procedures (send copies of the most recent results) ☐ TB ☐ HBsAg ☐ CMP ☐ CBC ☐ colonoscopy with tissue biopsy, date: _____
height: _____ in/cm weight: _____ lb/kg	Disease Staging ☐ MAYO score: _____ ☐ CDAI score: _____
Severity: ☐ mild ☐ moderate ☐ severe	

Treatment History

Current medication(s) with date(s) started: _____
 Prior medication(s) with dates of use: _____

PRESCRIPTION

☐ DAW (deliver to ☐ patient ☐ office)

Medication	Route	Dose/Strength	Directions/Sig	Quantity	Refills
☐ Check this box to authorize the pharmacy to interchange to the plan's preferred biosimilar if needed					
☐ ustekinumab ☐ Imuldosa ☐ Stelara ☐ Otulfi ☐ Steqeyma ☐ Pyzchiva ☐ Wezlana ☐ Selarsdi ☐ Yesintek ☐ Starjemza	IV sub-Q	☐ vial: 130mg/26mL ☐ PFS: 90mg/mL	☐ Induction: infuse _____ IV as a single dose ☐ 260mg (≤ 55 kg) ☐ 390mg (55-85kg) ☐ 520mg (> 85 kg) ☐ Maintenance: 90mg sub-Q every 8 weeks	60	0
☐ Xeljanz	PO	IR Tabs: ☐ 5mg ☐ 10mg XR Tabs: ☐ 11mg ☐ 22mg IR Tabs: ☐ 5mg ☐ 10mg XR Tabs: ☐ 11mg ☐ 22mg	Induction ☐ IR: 10mg PO BID for _____ weeks ☐ ER: 22mg PO once daily for _____ weeks Maintenance ☐ IR: 5mg PO BID ☐ ER: 11mg PO once daily ☐ other: _____		
☐ Other:					

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	

IRRITABLE BOWEL SYNDROME REFERRAL FORM

PATIENT INFORMATION (please attach insurance card)

Name:		☐ M ☐ F	DoB:	
Street:		City:		State:
Phone:	Phone:	Allergies:		

CLINICAL INFORMATION (please attach clinical notes and labs)

Diagnosis with ICD-10 code

- ☐ **A04.9** small intestine bacterial overgrowth (SIBO)
- ☐ **K58** irritable bowel syndrome (IBS), unspecified
- ☐ **K58.0** irritable bowel syndrome with diarrhea (IBS-D)
- ☐ **K58.1** irritable bowel syndrome with constipation (IBS-C)
- ☐ **K59.03** opioid-induced constipation (OIC)
- ☐ **K59.04** chronic idiopathic constipation (CIC)
- ☐ Other: _____

- ☐ If the diagnosis is SIBO, has the patient completed a diagnostic breath test? If yes, *please include results*. ☐ yes ☐ no
- ☐ If the diagnosis is IBS-D, has the patient failed a ≥ 3 month trial of dietary (low FODMAP diet) and lifestyle modifications? ☐ yes ☐ no
- ☐ If the diagnosis is IBS-C, OIC, or CIC, has the patient failed a ≥ 3 month trial of dietary (increased water, fiber) and lifestyle (increased exercise) modifications? ☐ yes ☐ no
- ☐ If the diagnosis is OIC, is the patient using the opioid(s) for chronic, non-cancer pain? ☐ yes ☐ no
- ☐ If the diagnosis is OIC, is the patient on a stable opioid dose not requiring frequent titrations? ☐ yes ☐ no

PRESCRIPTION

☐ DAW

Medication	Product	Directions/Sig	Quantity	Refills
Constipation				
☐ Ibsrela	50mg tab	1 tablet PO twice daily before meals		
☐ Linzess	Caps: ☐ 72mcg ☐ 145mcg ☐ 290mcg	1 capsule PO once daily 30 min before first meal		
☐ lubiprostone (Amitiza)	Caps: ☐ 8mcg ☐ 24mcg	1 capsule PO twice daily with meals		
☐ Motegrity	Tab: ☐ 1mg ☐ 2mg	1 tablet PO once daily		
☐ Movantik	Tab: ☐ 12.5mg ☐ 25mg	1 tablet PO once daily 1-2 hours before first meal		
☐ Relistor	Vial: ☐ 8mg/0.4mL ☐ 12mg/0.6mL Tab: ☐ 150mg tab	sub-Q: _____ mg every _____ day(s) PO: _____ mg PO once daily		
☐ Symproic	0.2mg tab	1 tablet PO once daily		
☐ Trulance	3mg tab	1 tablet PO once daily		
Diarrhea				
☐ alosetron	Tab: ☐ 0.5mg ☐ 1mg			
☐ Xifaxan	550mg tab	1 tablet PO three times daily for 14 days		
Other:				

PRESCRIBER INFORMATION

Prescriber:		Supervising Physician:	
Contact Name:	Contact Method: ☐ Phone ☐ Fax ☐ Email:		
Phone:	Ext:	Fax:	
Street:	City:	State:	Zip:
Signature:	Date:	NPI:	